Literature DB >> 18664629

Differential coupling of Arg- and Gly389 polymorphic forms of the beta1-adrenergic receptor leads to pathogenic cardiac gene regulatory programs.

Steven M Swift1, Brigitte R Gaume, Kersten M Small, Bruce J Aronow, Stephen B Liggett.   

Abstract

The beta(1)-adrenergic receptor (beta(1)AR; ADRB1) polymorphism Arg389Gly is located in an intracellular loop and is associated with distinct human and mouse cardiovascular phenotypes. To test the hypothesis that beta(1)-Arg389 and beta(1)-Gly389 alleles could differentially couple to pathways beyond that of classic G(s)-adenylyl cyclase (AC)/cAMP signaling, we performed comparative gene expression profile analyses on hearts from wild-type and transgenic mice that expressed either human beta(1)-Arg389 or beta(1)-Gly389 receptors, or AC5, sampling at an early age prior to the onset of pathological features. All three models upregulated the expression of genes associated with RNA metabolism and translation and downregulated genes associated with mitochondria and energy metabolism, consistent with shared cAMP-driven increase in cardiac contractility, protein synthesis, and compensatory downregulation of mitochondrial energy production. Both beta(1)AR alleles activated additional genes associated with other pathways. Uniquely, beta(1)-Arg389 hearts exhibited upregulated expression of genes associated with inflammation, programmed cell death, and extracellular matrix. These observations expand the scope of 7-transmembrane domain receptor signaling propagation beyond known cognate G protein couplings. Moreover, they implicate alterations of a repertoire of processes evoked by a single amino acid variation in the cardiac beta(1)AR that might be exploited for genotype-specific heart failure diagnostics and therapeutics.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18664629      PMCID: PMC2536824          DOI: 10.1152/physiolgenomics.90225.2008

Source DB:  PubMed          Journal:  Physiol Genomics        ISSN: 1094-8341            Impact factor:   3.107


  31 in total

Review 1.  Immune inhibitory receptors.

Authors:  J V Ravetch; L L Lanier
Journal:  Science       Date:  2000-10-06       Impact factor: 47.728

2.  Polymorphism in the beta(1)-adrenergic receptor gene and hypertension.

Authors:  K Bengtsson; O Melander; M Orho-Melander; U Lindblad; J Ranstam; L Råstam; L Groop
Journal:  Circulation       Date:  2001-07-10       Impact factor: 29.690

3.  A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade.

Authors:  G G Sofowora; V Dishy; M Muszkat; H G Xie; R B Kim; P A Harris; H C Prasad; D W Byrne; U B Nair; A J J Wood; C M Stein
Journal:  Clin Pharmacol Ther       Date:  2003-04       Impact factor: 6.875

4.  Polymorphisms of the beta1-adrenergic receptor predict exercise capacity in heart failure.

Authors:  Lynne E Wagoner; Laura L Craft; Paul Zengel; Nancy McGuire; Deborah A Rathz; Gerald W Dorn; Stephen B Liggett
Journal:  Am Heart J       Date:  2002-11       Impact factor: 4.749

5.  Increased myocardial expression of osteopontin in patients with advanced heart failure.

Authors:  Philipp Stawowy; Florian Blaschke; Peter Pfautsch; Stephan Goetze; Frank Lippek; Brigitte Wollert-Wulf; Eckart Fleck; Kristof Graf
Journal:  Eur J Heart Fail       Date:  2002-03       Impact factor: 15.534

6.  Altering the receptor-effector ratio by transgenic overexpression of type V adenylyl cyclase: enhanced basal catalytic activity and function without increased cardiomyocyte beta-adrenergic signalling.

Authors:  N M Tepe; J N Lorenz; A Yatani; R Dash; E G Kranias; G W Dorn; S B Liggett
Journal:  Biochemistry       Date:  1999-12-14       Impact factor: 3.162

7.  Persistent over-expression of specific CC class chemokines correlates with macrophage and T-cell recruitment in mdx skeletal muscle.

Authors:  John D Porter; Wei Guo; Anita P Merriam; Sangeeta Khanna; Georgiana Cheng; Xiaohua Zhou; Francisco H Andrade; Chellah Richmonds; Henry J Kaminski
Journal:  Neuromuscul Disord       Date:  2003-03       Impact factor: 4.296

8.  Antigen processing and presentation in human muscle: cathepsin S is critical for MHC class II expression and upregulated in inflammatory myopathies.

Authors:  Heinz Wiendl; Alfred Lautwein; Meike Mitsdörffer; Sabine Krause; Stella Erfurth; Wolfgang Wienhold; Matthias Morgalla; Ekkehard Weber; Herman S Overkleeft; Hanns Lochmüller; Arthur Melms; Eva Tolosa; Christoph Driessen
Journal:  J Neuroimmunol       Date:  2003-05       Impact factor: 3.478

9.  Hierarchy of polymorphic variation and desensitization permutations relative to beta 1- and beta 2-adrenergic receptor signaling.

Authors:  Deborah A Rathz; Kimberly N Gregory; Ying Fang; Kari M Brown; Stephen B Liggett
Journal:  J Biol Chem       Date:  2003-01-13       Impact factor: 5.157

10.  Improved human disease candidate gene prioritization using mouse phenotype.

Authors:  Jing Chen; Huan Xu; Bruce J Aronow; Anil G Jegga
Journal:  BMC Bioinformatics       Date:  2007-10-16       Impact factor: 3.169

View more
  4 in total

Review 1.  Mechanisms of pharmacogenomic effects of genetic variation within the cardiac adrenergic network in heart failure.

Authors:  Gerald W Dorn; Stephen B Liggett
Journal:  Mol Pharmacol       Date:  2009-06-02       Impact factor: 4.436

Review 2.  Pharmacogenomics of beta1-adrenergic receptor polymorphisms in heart failure.

Authors:  Stephen B Liggett
Journal:  Heart Fail Clin       Date:  2010-01       Impact factor: 3.179

3.  Temporal analysis of mRNA and miRNA expression in transgenic mice overexpressing Arg- and Gly389 polymorphic variants of the β1-adrenergic receptor.

Authors:  Karen Dockstader; Karin Nunley; Anis Karimpour-Fard; Allen Medway; Penny Nelson; J David Port; Stephen B Liggett; Michael R Bristow; Carmen C Sucharov
Journal:  Physiol Genomics       Date:  2011-09-27       Impact factor: 3.107

4.  Crystal structures of a stabilized β1-adrenoceptor bound to the biased agonists bucindolol and carvedilol.

Authors:  Tony Warne; Patricia C Edwards; Andrew G W Leslie; Christopher G Tate
Journal:  Structure       Date:  2012-05-09       Impact factor: 5.006

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.